Dr. Jacob Chacko is the CEO of ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers. He was previously chief financial officer of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche for $1.7 billion. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion.
He has served on the board of directors of Bonti, RentPath and EnvisionRx and was a board observer to Par Pharmaceutical, IMS Health and Quintiles Transnational. In addition, he previously served on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford. He currently serves on the board of directors of 4D Molecular Therapeutics and chairs the Western Regional Selection Committee for the Marshall Scholarship.
Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his MBA with distinction from Harvard Business School. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company. He received a M.Sc. from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the university valedictorian.